Optimizing Adherence and AE Management to Luspatercept

Luspatercept is typically administered as a subcutaneous injection every three weeks, with dosing adjusted based on hemoglobin response and tolerability. Patient education focuses on the injection schedule, proper administration technique, potential side effects, and the importance of adherence to achieve optimal outcomes. Best practices for supporting adherence include clear communication, reminder systems, and routine follow-up to assess response and address concerns. Common adverse events include fatigue, headache, hypertension, and musculoskeletal pain, which are generally manageable with supportive care or dose modifications. Monitoring involves regular hemoglobin checks, blood pressure assessments, and evaluation for any new or worsening symptoms. Prompt recognition and proactive management of side effects are critical to maintaining therapy continuity and maximizing clinical benefit, ensuring patients derive the full potential advantage of luspatercept in managing anemia associated with low-risk MDS.